The chart above plots the price of BIO over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 61 sessions over that window: $292 on 11 June 2026 through $380 on 8 September 2026.
Market cap$10.2B
52-week range$242 – $390.31
Avg volume38.4K
Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Sep 9, 2026
Filings 4 sets
BIO reported financials
SEC EDGAR XBRL
BIO reported revenue of $2.6B for the fiscal year ended 31 Dec 2025. Net income over the same period was $759.9M.
FigureReportedPeriod
Revenue
$2.6B
31 Dec 2025 fiscal year
Net income
$759.9M
31 Dec 2025 fiscal year
Diluted EPS
$27.85
31 Dec 2025 fiscal year
Total assets
$10.3B
30 Jun 2026 at period end
Total equity
$7.2B
30 Jun 2026 at period end
Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
BIO earnings
SEC EDGAR
DatePeriodEPSRevenue
30 Jun 2026Q2 2026$13.85$651M
31 Mar 2026Q1 2026$-19.55$592M
31 Dec 2025FY 2025$27.85$2.58B
30 Sep 2025Q3 2025$-12.70$653M
30 Jun 2025Q2 2025$11.67$652M
31 Mar 2025Q1 2025$2.29$585M
31 Dec 2024FY 2025$-25.57$2.57B
30 Sep 2024Q3 2024$23.34$650M
Next report no date announced in SEC filings yet
Reported figures & scheduled dates · SEC EDGAR filings
10 of the 45 institutional funds we track reported a BIO position for the quarter ended 30 Jun 2026 — a combined $155.7M; the latest of those filings landed 02 Sep 2026.